FIELD: organic chemistry, hormones, pharmacy.
SUBSTANCE: invention relates to compounds of the formula (I) or (II)
or to their pharmaceutically acceptable salts wherein each Y and Z in each case represents independently D- or L-natural or non-natural α-amino acid; n in each case means independently 0 or 4, (I) under condition that both n can't mean simultaneously 0; and 0 or 4 (II) wherein indicated amino acids (in I) represent the chain: X1-X2-X3-X4 wherein X1 represents Tyr or Trp residues that can be protected with the Boc-group; X2 represents D-Trp; X represents Lys that can be protected with the Boc-group; X4 represents Nal, Tyr or Thr; m = 0; a means hydrogen atom (H) or R1; b means -OH or -OR1; for (II) X1 represents natural or non-natural D- or L-isomer of Phe, Trp or Tyr wherein when X1 means Tyr then the aromatic ring in its by-side chain is substituted with R6 optionally; X2 represents D- or L-isomer of Trp; X3 represents Lys; X4 represents natural or non-natural D- or L-amino acid Nal, Thr, Tyr or Ser wherein when X4 represents Tyr then the aromatic ring disposed in its by-side chain can be substituted with R6 optionally; or when X4 represents Ser or Thr then oxygen atom disposed in its by-side chain can be substituted with one or some R1 wherein R1 represents hydrogen atom (H), or (C1-C4)-alkyl (I); for (II) R1 means hydrogen atom (H), (C1-C4)-alkyl or aryl-(C1-C4)-alkyl; R2 represents hydrogen atom (H) or substituted phenyl-(C1-C4)-alkyl for (I); for (II): R2 means substituted phenyl-(C1-C4)-alkyl; R3 and R each represents independently hydrogen atom (H), or substituted aryl that can be substituted with one or some substitutes taken among the group consisting of hydroxy-group (OH), (C1-C4)-alkyl and (C1-C4)-alkoxy-group; in each case R5 represents hydrogen atom (H); R3 and R each represents independently hydrogen atom (H) or optionally substituted fragment taken among the group consisting of (C1-C4)-alkyl and aryl being optionally substituted fragment is substituted with one or some substituted taken among the group consisting of -OH and (C1-C4)-alkoxy-group; in each case R5 represents independently hydrogen atom (H); R6 represents in each case aryl-(C1-C4)-alkyl. Invention relates to two pharmaceutical compositions used for the selective binding with at least one of subtype of the human somatostatin receptor comprising in the effective dose compound of the formula (I) of compound of the formula (II).
EFFECT: valuable medicinal properties of compounds.
17 cl, 2 tbl, 22 ex
Title | Year | Author | Number |
---|---|---|---|
NEUROMEDIN AND SOMATOSTATIN RECEPTOR AGONISTS | 2000 |
|
RU2263680C2 |
PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
CHIMERIC EQUIVALENTS OF LIGANS OF SOMATOSTATIN AND DOPERMINE RECEPTORS, PHARMACEUTICAL COMPOSITIONS BASED ON THEM AND MODALTIES OF SOMATOSTATIN AND/DOPERMINE RECEPTORS | 2004 |
|
RU2329273C2 |
GLP-1 ANALOGS | 1999 |
|
RU2288232C9 |
SOMATOSTATIN RECEPTOR ANTAGONISTS | 1997 |
|
RU2179172C2 |
ANALOGUES OF PEPTIDE LH-RF, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEREOF | 1998 |
|
RU2212247C2 |
CYCLIC PEPTIDES, RADIOPHARMACEUTICAL PREPARATION, AND RADIOACTIVELY LABELED CYCLIC PEPTIDES | 1994 |
|
RU2145608C1 |
CHIMERIC ANALOGS OF SOMATOSTATIN-DOPAMINE | 2002 |
|
RU2277539C2 |
METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
INHIBITORS OF VIIA FACTOR | 1999 |
|
RU2223967C2 |
Authors
Dates
2004-12-20—Published
1999-06-11—Filed